Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIGN: Melphalan/HDS vs Cisplatin/Gemcitabine in Intrahepatic Cholangiocarcinoma
NCT03086993Phase 3Unknown
- Sponsor
- Delcath Systems
- Start
- Apr 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Delcath Systems. Primary endpoint: Overall Survival at 2 years. Status: unknown.
02
Drugs
melphalan
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03086993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086993.